Newron says Phase 3 ENIGMA-TRS 1 enrollment to complete mid-October, topline data due Q1 2027
Bitget2026/10/08 05:01Newron received FDA written feedback keeping a clinical hold in place at U.S. centers in the Phase 3 ENIGMA-TRS 2 study. The agency flagged a potential cardiac safety signal tied to deaths in the evenamide program, prompting added screening plans. Management is reviewing the feedback, preparing a response, and has not reported new trial results in this update. ENIGMA-TRS 1 enrollment is expected to finish by mid-October, with topline 12-week data due in Q1 2027. ENIGMA-TRS 2 enrollment continues outside the U.S., with additional sites being added while the U.S. pause remains. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2412180_en) on October 08, 2026, and is solely responsible for the information contained therein.
- Newron received FDA written feedback keeping a clinical hold in place at U.S. centers in the Phase 3 ENIGMA-TRS 2 study.
- The agency flagged a potential cardiac safety signal tied to deaths in the evenamide program, prompting added screening plans.
- Management is reviewing the feedback, preparing a response, and has not reported new trial results in this update.
- ENIGMA-TRS 1 enrollment is expected to finish by mid-October, with topline 12-week data due in Q1 2027.
- ENIGMA-TRS 2 enrollment continues outside the U.S., with additional sites being added while the U.S. pause remains.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
